Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
Type:
Grant
Filed:
June 7, 2022
Date of Patent:
April 30, 2024
Assignee:
Clarity Pharmaceuticals Ltd
Inventors:
Nicholas Alan Zia, Paul Stephen Donnelly
Abstract: The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
Type:
Grant
Filed:
June 13, 2022
Date of Patent:
April 23, 2024
Assignee:
GE Healthcare Limited
Inventors:
Torgrim Engell, Julian Grigg, Dimitrios Mantzilas, Dag M. Evje
Abstract: Radiopaque hydrogels, in particular radiopaque hydrogel microspheres, comprising a polymer having 1,2-dil or 1,3-diol groups acetalized with radiopaque species.
Type:
Grant
Filed:
May 25, 2021
Date of Patent:
April 16, 2024
Assignee:
Boston Scientific Medical Device Limited
Inventors:
Stephane Hohn, Andrew Lennard Lewis, Sean Leo Willis, Matthew R. Dreher, Koorosh Ashrafi, Yiqing Tang
Abstract: Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.
Type:
Grant
Filed:
September 17, 2019
Date of Patent:
April 16, 2024
Assignee:
SYNEDGEN, INC.
Inventors:
Shenda M. Baker, William P. Wiesmann, Stacy Marie Townsend
Abstract: The invention provides a chromogenic ?-lactam molecule that retains its diagnostic color change response when modified for conjugation to another molecule.
Abstract: The present disclosure relates to a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd3+ ion, and R1, R2, R3, R4 and R5 are as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.
Type:
Grant
Filed:
November 21, 2019
Date of Patent:
April 2, 2024
Assignee:
BAYER AKTIENGESELLSCHAFT
Inventors:
Stephan Holzschuh, Thomas Frenzel, Gregor Jost, Jessica Lohrke, Wolfgang Ebert, Thomas Brumby, Wolfgang Halfbrodt
Abstract: The present invention discloses a method for preventing retraction of aqueous drops on a hydrophobic surface. The present invention also discloses a medical device coated with a hydrophilic coating comprising a substrate and a coating composition.
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
March 12, 2024
Assignee:
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
Abstract: The invention encompasses components from microbial cells which are useful for antibody production, including peptides, polypeptides comprising these peptides, polynucleotides which encode these peptides or polypeptides, and antibodies directed to these peptides, polypeptides, or polynucleotides. The invention also encompasses to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further encompasses methods and compositions, especially vaccine compositions, for detecting, targeting, and inhibiting microbial cells, especially methanogen cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.
Type:
Grant
Filed:
April 8, 2021
Date of Patent:
March 12, 2024
Assignee:
Pastoral Greenhouse Gas Research Limited
Inventors:
Eric Heinz Altermann, Graeme Trevor Attwood, Dong Li, William John Kelly, Zhanhao Kong, Sinead Christine Leahy
Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
Type:
Grant
Filed:
August 4, 2020
Date of Patent:
February 27, 2024
Assignee:
THE JOHNS HOPKINS UNIVERSTY
Inventors:
Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
Type:
Grant
Filed:
August 4, 2021
Date of Patent:
February 20, 2024
Assignee:
Clarity Pharmaceuticals Ltd.
Inventors:
Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
Abstract: The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency.
Abstract: Nanoparticle compositions for delivery of nucleic acids to subjects including carriers comprising sugar functionalized nucleic acid carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the delivery molecules are described. Methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects are provided.
Abstract: Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein.
Abstract: The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I) or a pharmaceutically acceptable salt thereof, the preparation comprising leachable tin at a level of 0 ppm to 850 ppm.
Abstract: One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer.
Type:
Grant
Filed:
April 23, 2021
Date of Patent:
November 28, 2023
Assignee:
HyperBranch Medical Technology, Inc.
Inventors:
Kenneth E. Stockman, Michael A. Carnahan, Keith R. D'Alessio, Mark W. Grinstaff
Abstract: A compound comprising an oligomer formed from a biocompatible multifunctional carboxylic acid comprising a hydroxyl group and at least one carboxylic acid, an polyol (e.g., an aliphatic diol), and a linker. One or more conductive oligomers (e.g., polyanilines) are covalently bonded to the oligomer. The compounds can have various forms (e.g., articles of manufacture, films, scaffolds, and the like). The compounds have various uses. For example, the compounds are used in photoacoustic imaging methods.
Abstract: The present disclosure pertains to crosslinkable compositions and systems as well as methods for forming crosslinked compositions in situ, including the use of the same for controlling the movement of bodily fluid within a patient, among many other uses.
Type:
Grant
Filed:
March 21, 2022
Date of Patent:
October 24, 2023
Assignee:
Medtronic Vascular, Inc.
Inventors:
Craig Wiltsey, Nikhita Mansukhani, Jeffrey Groom, II, Kate Rielly, Changcheng You, Danny Concagh
Abstract: The present disclosure features a protein-polymer conjugate, including a multivalent polymer building block, a stimuli-responsive protein covalently conjugated to the multivalent polymer building block to provide a protein-polymer conjugate, wherein the protein undergoes a modification upon exposure to a predetermined stimulus, and the protein modification triggers a physical and/or chemical response in the protein-polymer conjugate.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
October 10, 2023
Assignee:
University of Washington
Inventors:
Cole Alexander DeForest, Jared Shadish, Luman Liu